Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents
Myriad expands pharma service offering by introducing Personalis’ ImmunoID NeXT® platform to its pharmaceutical partners who use MyRisk® Hereditary Cancer Test, BRACAnalysis CDx® and/or MyChoice® CDx cancer tests
New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood
Nearly three out of four women falsely believe a pap smear will reveal ovarian cancer presence
Myriad Genetics announced Great Place To Work® and Fortune magazine have named Myriad Genetics to the 2023 Fortune Best Workplaces in Health Care™ List.
Prolaris is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1
Myriad Genetics announced enhancements to the GeneSight® Psychotropic test.
ComboMATCH study uses genetic testing to match advanced cancer patients with targeted treatments
RiskScore is the first validated risk model that includes breast density, personal/family history and genetic markers. This comprehensive model is expected to identify more patients that could benefit from a change in their breast care.
Myriad to support MD Anderson researchers studying metastatic renal cell carcinoma treatment selection and response
$67.5 million tuck-in acquisition strengthens Myriad’s Women’s Health portfolio of prenatal products.
Myriad Genetics announced financial results for its third quarter ended September 30, 2022 and provided an update on business performance.